Richard Heyman trims 6,700 Oric Pharmaceuticals (ORIC) shares via plan

Rhea-AI Filing Summary

Oric Pharmaceuticals director Richard A. Heyman reported planned stock sales under a Rule 10b5-1 trading plan shared with RAHD Capital, LLC. On January 16, 2026, he sold 3,500 shares of common stock directly at a weighted average price of $12.0046, leaving 41,800 shares held directly. The same day, 3,200 additional shares were sold indirectly at the same weighted average price, with 213,072 shares then held of record by RAHD Capital, LLC, over which he has voting and investment power. In total, the filing notes a weighted average price for 6,700 shares sold in a price range of $12.00 to $12.03.

Insider Trade Summary

Net Seller: 6,700 shares ($80,431)

Net Sell 2 txns

Insider Heyman Richard A.

Role Director

Sold 6,700 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,500	$12.0046	$42K
Sale	Common Stock	3,200	$12.0046	$38K

Holdings After Transaction: Common Stock — 41,800 shares (Direct); Common Stock — 213,072 shares (Indirect, See footnote)

Footnotes (1)

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		S(1)		3,500	D	$12.0046(2)	41,800	D
Common Stock	01/16/2026		S(1)		3,200	D	$12.0046(2)	213,072	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

2. Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

	/s/ Christian Kuhlen, attorney-in-fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ORIC report in this Form 4?

The filing shows Richard A. Heyman, a director of Oric Pharmaceuticals, sold a total of 6,700 shares of common stock on January 16, 2026, including both direct and indirect holdings.

How many ORIC shares did Richard A. Heyman sell directly and at what price?

He sold 3,500 shares of Oric Pharmaceuticals common stock directly at a weighted average price of $12.0046 per share.

What indirect ORIC share sale is disclosed for Richard A. Heyman?

An additional 3,200 shares of common stock were sold indirectly at a weighted average price of $12.0046 per share, with the shares held of record by RAHD Capital, LLC.

How many ORIC shares does Richard A. Heyman hold after these transactions?

Following the sales, he beneficially owns 41,800 shares directly and 213,072 shares indirectly through RAHD Capital, LLC, over which he has voting and investment power.

Were the ORIC insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Richard A. Heyman and RAHD Capital, LLC.

What price range is disclosed for the ORIC shares sold in this filing?

The filing notes a weighted average price for an aggregate of 6,700 shares sold in a price range of $12.00 to $12.03 per share.